NICE accepts aripiprazole for bipolar disorder in adolescents

NICE has approved the use of aripiprazole (Abilify) in adolescents with bipolar I disorder for treating moderate to severe manic episodes.

Abilify is also approved by NICE for treating schizophrenia in patients aged 15 to 17 years when risperidone is unsuitable.
Abilify is also approved by NICE for treating schizophrenia in patients aged 15 to 17 years when risperidone is unsuitable.

The atypical antipsychotic aripiprazole (Abilify) is recommended by NICE for use within its licensed indication in adolescents aged 13 years and over for up to 12 weeks.

It is also approved for use on the NHS by NICE for treating schizoprenia in patients aged 15–17 years when risperidone is contraindicated, not tolerated or does not provide adequate symptom control.

View Abilify drug record

NICE guidance on aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more